Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Bimatoprost

    Client Email Product

    Bimatoprost

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Related ProductsRelated Products
    API SUPPLIERS
    API Suppliers

    API Suppliers

    40
    US DMFs Filed

    US DMFs Filed

    13
    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    6
    Other Certificates

    Other Certificates

    3
    Other Suppliers

    Other Suppliers

    29
    API REF. PRICE (USD / KG)
    668,809

    API Market Place

    15
    INTERMEDIATES
    7
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    22
    Europe

    Europe

    33
    Canada

    Canada

    7
    Australia

    Australia

    13
    South Africa

    South Africa

    3
    Uploaded Dossiers

    Uploaded Dossiers

    20
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    4,286.00

    Annual Reports

    684.00

    FDF Market Place

    3
    EXCIPIENTS
    6
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    24

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    1

    News

    40
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    1
    SERVICES

    0

    Full View ScreenFull Screen View
    Sandoz must cough up $39M after losing Allergan patent fight
    Sandoz must cough up $39M after losing Allergan patent fight

    https://www.fiercepharma.com/pharma/sandoz-loses-patent-fight-allergan-and-duke-u-must-cough-39m

    Kevin Dunleavy FIERCE PHARMA
    04 Apr 2023
    Share Share
    Sandoz to pay Allergan, Duke University $39M over eye drug lawsuit
    Sandoz to pay Allergan, Duke University $39M over eye drug lawsuit

    https://endpts.com/sandoz-must-pay-allergan-duke-university-39m-over-latisse-lawsuit-jury-says/

    Katherine Lewin ENDPTS
    03 Apr 2023
    Share Share
    Eugia's Generic Bimatoprost Receives Approval in the U.S.
    Eugia's Generic Bimatoprost Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205537

    FDA
    06 Oct 2022
    Share Share
    Allergan to Present Data from its Leading Portfolio of Eye Care Treatments
    Allergan to Present Data from its Leading Portfolio of Eye Care Treatments

    https://www.prnewswire.com/news-releases/allergan-an-abbvie-company-to-present-data-from-its-leading-portfolio-of-eye-care-treatments-at-the-2022-american-glaucoma-society-ags-annual-meeting-301489901.html

    PRNEWSWIRE
    24 Feb 2022
    Share Share
    Micro Labs`s Generic Bimatoprost Receives Approval In US
    Micro Labs`s Generic Bimatoprost Receives Approval In US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204638

    FDA
    19 May 2021
    Share Share
    FAMAR & Medicom announce the acquisition by Medicom dossier of BIMATOPROST
    FAMAR & Medicom announce the acquisition by Medicom dossier of BIMATOPROST

    https://famar-group.com/new/famar-medicom-acquisition-bimatoprost/

    PRESS RELEASE
    09 Feb 2021
    Share Share
    Micro Labs's Generic Bimatoprost Receives Approval In US
    Micro Labs's Generic Bimatoprost Receives Approval In US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202505

    FDA
    08 Sep 2020
    Share Share
    FDA approves Allergan's long-term eye implant for glaucoma
    FDA approves Allergan's long-term eye implant for glaucoma

    https://www.fiercebiotech.com/medtech/fda-approves-allergan-s-long-term-eye-implant-for-glaucoma

    Conor Hale FIERCE BIOTECH
    05 Mar 2020
    Share Share
    Allergan Receives FDA Approval for DURYSTA
    Allergan Receives FDA Approval for DURYSTA

    https://www.prnewswire.com/news-releases/allergan-receives-fda-approval-for-durysta-bimatoprost-implant-the-first-and-only-intracameral-biodegradable-sustained-release-implant-to-lower-intraocular-pressure-in-open-angle-glaucoma-or-ocular-hypertension-patients-301017349.html

    PR NEWSWIRE
    05 Mar 2020
    Share Share
    Allergan to Present New Data for Investigational Bimatoprost Sustained-Release
    Allergan to Present New Data for Investigational Bimatoprost Sustained-Release

    https://www.prnewswire.com/news-releases/allergan-to-present-new-data-for-investigational-bimatoprost-sustained-release-at-american-glaucoma-society-annual-meeting-301010115.html

    PR NEWSWIRE
    25 Feb 2020
    Share Share
    Alembic Pharma's Generic Bimatoprost Receives Approval in U.S
    Alembic Pharma's Generic Bimatoprost Receives Approval in U.S

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210515

    FDA
    21 Jan 2020
    Share Share
    Enforcement Report - Week of January 8, 2020
    Enforcement Report - Week of January 8, 2020

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-8-2020-1578473645.pdf

    FDA
    08 Jan 2020
    Share Share
    Enforcement Report - Week of November 6, 2019
    Enforcement Report - Week of November 6, 2019

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-november-6-2019-1573017375.pdf

    FDA
    06 Nov 2019
    Share Share
    Alembic Pharma’s Generic Bimatoprost Receives Approval In US
    Alembic Pharma’s Generic Bimatoprost Receives Approval In US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210144

    FDA
    09 Aug 2019
    Share Share
    Somerset Therapeutics' Generic Bimatoprost Receives Approval in US
    Somerset Therapeutics' Generic Bimatoprost Receives Approval in US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207601

    FDA
    19 Jun 2019
    Share Share
    Alembic Pharms Generic Bimatoprost Receives Approval in US
    Alembic Pharms Generic Bimatoprost Receives Approval in US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210263

    FDA
    17 Apr 2019
    Share Share
    Enforcement Report - Week of February 13, 2019
    Enforcement Report - Week of February 13, 2019

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-13-2019-1550065023.pdf

    FDA
    13 Feb 2019
    Share Share
    Hi-Tech Pharma's Generic Bimatoprost Receives Approval in US
    Hi-Tech Pharma's Generic Bimatoprost Receives Approval in US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203299

    FDA
    13 Nov 2018
    Share Share
    Gland Pharma's Generic Bimatoprost Receives Tentative Approval in US
    Gland Pharma's Generic Bimatoprost Receives Tentative Approval in US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209797

    FDA
    03 Nov 2018
    Share Share
    Hi-Tech Pharmacal's Generic Bimatoprost Receives Approval in US
    Hi-Tech Pharmacal's Generic Bimatoprost Receives Approval in US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203051

    FDA
    10 Oct 2018
    Share Share
    Latisse (bimatoprost) : Allergan, Duke University vs. Akorn
    Latisse (bimatoprost) : Allergan, Duke University vs. Akorn

    https://insight.rpxcorp.com/litigation_documents/13072506

    PATENT LITIGATION
    22 Sep 2018
    Share Share
    Alembic Pharms' Generic Bimatoprost Receives Tentative Approval in US
    Alembic Pharms' Generic Bimatoprost Receives Tentative Approval in US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210515

    FDA
    06 Aug 2018
    Share Share
    Latisse® (bimatoprost): Duke University v. Alcon Laboratories
    Latisse® (bimatoprost): Duke University v. Alcon Laboratories

    https://www.pharmacompass.com/pdf/news/latisse-bimatoprost-duke-university-v-alcon-laboratories-1525671170.pdf

    PATENT LITIGATION
    05 May 2018
    Share Share
    Latisse® (Bimatoprost Ophthalmic Sol): Duke University v. Sandoz
    Latisse® (Bimatoprost Ophthalmic Sol): Duke University v. Sandoz

    https://www.pharmacompass.com/pdf/news/latisse-bimatoprost-ophthalmic-sol-duke-university-v-sandoz-1525069007.pdf

    PATENT LITIGATION
    26 Apr 2018
    Share Share
    Latisse®(bimatoprost): Duke University et al v. Sandoz Inc
    Latisse®(bimatoprost): Duke University et al v. Sandoz Inc

    https://insight.rpxcorp.com/litigation_documents/12865082

    PATENT LITIGATION
    03 Apr 2018
    Share Share
    Latisse®(bimatoprost): Duke University et al v. Alcon Laboratories, Inc.
    Latisse®(bimatoprost): Duke University et al v. Alcon Laboratories, Inc.

    https://insight.rpxcorp.com/litigation_documents/12865081

    PATENT LITIGATION
    03 Apr 2018
    Share Share
    Latisse® Lumigan® (Bimatoprost): Sandoz &Alcon Lab V. Duke University, Allergan
    Latisse® Lumigan® (Bimatoprost): Sandoz &Alcon Lab V. Duke University, Allergan

    https://insight.rpxcorp.com/litigation_documents/12616351

    PATENT LITIGATION
    14 Sep 2017
    Share Share
    Latisse® (Bimatoprost ): Duke University & Allergan Sales v. Sandoz & Alcon Laboratories
    Latisse® (Bimatoprost ): Duke University & Allergan Sales v. Sandoz & Alcon Laboratories

    https://www.pharmacompass.com/pdf/news/latisse-bimatoprost-duke-university-allergan-sales-v-sandoz-alcon-laboratories-1499676474.pdf

    PATENT LITIGATION
    07 Jul 2017
    Share Share
    Enforcement Report - Week of April 19, 2017
    Enforcement Report - Week of April 19, 2017

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-19-2017-1492575710.pdf

    FDA
    19 Apr 2017
    Share Share
    Allergan takes on preventable blindness with nationwide vision-screening push
    Allergan takes on preventable blindness with nationwide vision-screening push

    http://www.fiercepharma.com/marketing/allergan-takes-preventable-blindness-nationwide-vision-screening-push

    Carly Helfand FIERCE PHARMA
    09 Feb 2017
    Share Share
    Allergan Unveils Single-Digit Price Hikes for 9 Brand Name Drugs
    Allergan Unveils Single-Digit Price Hikes for 9 Brand Name Drugs

    http://www.biospace.com/News/as-promised-allergan-unveils-single-digit-price/443124/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews

    Alex Keown BIOSPACE
    04 Jan 2017
    Share Share
    Fitch Affirms Allergan at 'BBB-'; Outlook Stable
    Fitch Affirms Allergan at 'BBB-'; Outlook Stable

    http://www.reuters.com/article/idUSFit982851?rpc=401&

    REUTERS
    08 Dec 2016
    Share Share
    Sienna Biopharmaceuticals Acquires Creabilis plc
    Sienna Biopharmaceuticals Acquires Creabilis plc

    http://www.prnewswire.com/news-releases/sienna-biopharmaceuticals-acquires-creabilis-plc-300373769.html

    PR NEWSWIRE
    06 Dec 2016
    Share Share
    Allergan breaks ground on $200 million waco facility expansion
    Allergan breaks ground on $200 million waco facility expansion

    http://www.multivu.com/players/English/7818951-allergan-waco-tx-expansion/

    PR NEWSWIRE
    26 Apr 2016
    Share Share
    Bay Area’s Relypsa) Stock Pops (Again) on More Buyout Rumors
    Bay Area’s Relypsa) Stock Pops (Again) on More Buyout Rumors

    http://www.biospace.com/News/bay-areas-relypsa-stock-pops-again-on-more-buyout/416613/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews

    Mark Terry BIOSPACE
    22 Apr 2016
    Share Share
    Independent study from Baylor University shows the economic impact of Allergan
    Independent study from Baylor University shows the economic impact of Allergan

    http://www.prnewswire.com/news-releases/estudio-independiente-de-la-universidad-baylor-demuestra-el-impacto-economico-de-allergan-sobre-las-economias-de-waco-y-texas-central-567030331.html

    PR NEWS WIRE
    29 Jan 2016
    Share Share
    Alcon's Bimatoprost (0.03 %) Approved in USA For Ocular Hypertension
    Alcon's Bimatoprost (0.03 %) Approved in USA For Ocular Hypertension

    https://www.pharmacompass.com/pdf/news/n61.pdf

    Press Release FDA
    08 May 2015
    Share Share
    Attix Pharmaceuticals Recalls Hundreds of APIs From the U.S.
    Attix Pharmaceuticals Recalls Hundreds of APIs From the U.S.

    http://www.fiercepharmamanufacturing.com/story/attix-pharmaceuticals-recalls-hundreds-apis-us/2015-04-30

    Eric Palmer FIERCE PHARMA MFG
    02 May 2015
    Share Share
    Lupin 's Generic Lumigan (Bimatoprost Ophthalmic Solution 0.03 %) Approved in USA for Glaucoma or Ocular Hypertension
    Lupin 's Generic Lumigan (Bimatoprost Ophthalmic Solution 0.03 %) Approved in USA for Glaucoma or Ocular Hypertension

    http://www.lupin.com/pdf/2015/Lupin-Receives-FDA-Approval-for-Generic-Lumigan-Ophtahlmic-Solution-0-03.pdf

    Press Release LUPIN
    23 Feb 2015
    Share Share
    New Wave of Drugs Poised to Shake Up Glaucoma Treatment
    New Wave of Drugs Poised to Shake Up Glaucoma Treatment

    http://in.reuters.com/article/2015/02/10/us-health-glaucoma-idINKBN0LE0DG20150210?feedType=RSS&feedName=health&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+reuters%2FINhealth+%28News+%2F+IN+%2F+Health%29

    Toni Clarke REUTERS
    16 Feb 2015
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    Cayman Bimatoprost

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Gentec SA Bimatoprost

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search